Abstract: Aromatic heterocyclic compounds as ENPP1 inhibitors, a preparation method therefor and the uses thereof. The compounds have structures as shown in formula (I).

Abstract: A compound as shown in formula I, or an optical isomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a tautomer thereof, a mesomer thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, a mixture form thereof, a metabolite thereof, a metabolic precursor thereof, or an isotope substitute form thereof. TB is a target recognition/binding portion, L is a linking portion, and U is a ubiquitin protease recognition/binding portion, the three portions being connected by means of chemical bonds. The compound can significantly down-regulate mutated androgen receptor (AR) proteins, and has good inhibitory activity on prostate cancer cell lines.

Abstract: A system includes a computing device including at least one processor in communication with at least one memory. The at least one processor is programmed to (a) store a plurality of historical time series data; (b) randomly select a sequence; (c) randomly select a mask length for a mask for the selected sequence; (d) apply the mask to the selected sequence, wherein the mask is applied to the plurality of forecast variables in the selected sequence; (e) execute a model with the masked selected sequence to generate predictions for the masked forecast variables; (f) compare the predictions for the masked forecast variables to the actual forecast variables in the selected sequence; (g) determine if convergence occurs based upon the comparison; and (h) if convergence has not occurred, update one or more parameters of the model and return to step b.

Abstract: Bifunctional chimeric heterocyclic compounds of formula (I) is effective for targeted degradation of androgen receptors and use thereof. The compound of formula (I) also has an isotopic compound, an optical isomer, a tautomer, pharmacologically acceptable salt, a prodrug thereof, or a solvate. In formula (I), ARB is an androgen receptor recognition/binding part, L is a link part, and U is a ubiquitin protease recognition/binding part; and the three parts are connected by means of chemical bonds. The compound can perform targeted degradation on androgen receptors in prostate cancer cells, and suppress proliferation of the prostate cancer cells, and also show good metabolic stability and pharmacokinetic properties. The compound has good application prospect in preparation of targeted chimeras for protein degradation of androgen receptors and in the preparation of drugs for treating related diseases regulated by the androgen receptors.

Abstract: Embodiments of the present invention provide an adaptive voltage scaling method, chip, and device. An aging effect-related state parameter in a chip is obtained at a first voltage adjustment time point. The first voltage adjustment time point is one of multiple voltage adjustment time points set for the chip. An aging compensation voltage corresponding to the first voltage adjustment time point is determined according to the state parameter. A minimum operating voltage of the chip is compensated for according to the aging compensation voltage, so as to adjust an operating voltage of the chip.

Abstract: Embodiments of the present invention provide an adaptive voltage scaling method, chip, and device. An aging effect-related state parameter in a chip is obtained at a first voltage adjustment time point. The first voltage adjustment time point is one of multiple voltage adjustment time points set for the chip. An aging compensation voltage corresponding to the first voltage adjustment time point is determined according to the state parameter. A minimum operating voltage of the chip is compensated for according to the aging compensation voltage, so as to adjust an operating voltage of the chip.